2016 Fiscal Year Final Research Report
Tumor-Inhibition Effect of Levetiracetam in Combination with Temozolomide in Glioblastoma Cells
| Project/Area Number |
26462188
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Neurosurgery
|
|---|
| Research Institution | Nara Medical University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Keywords | glioblastoma / levetiracetam / temozolomide / premature senescence |
|---|
| Outline of Final Research Achievements |
Glioblastoma (GBM) is a malignant brain tumor with a poor prognosis. The standard postoperative chemotherapy is temozolomide (TMZ), which does not greatly improve survival. Antiepileptic drug levetiracetam (LEV) is commonly prescribed, but the therapeutic advantages of the LEV and TMZ combination remain poorly understood.
We evaluated cell proliferation and premature senescence after single and combined treatments of TMZ and LEV in several GBM cell lines that differ in TMZ sensitivity. Both LEV and TMZ reduced cell proliferation in a dose-dependent manner in A172 cells. A senescent-like phenotype was induced by both TMZ and LEV. Overall, there was a greater effect following combined treatment compared to the monotherapy groups. Thus, LEV appears to have a tumor-suppressive effect and induces cellular senescence, and combined treatment of LEV and TMZ enhanced these effects. LEV use in GBM treatment may allow for reduction of the TMZ dose to enhance the clinical efficacy of TMZ.
|
| Free Research Field |
脳腫瘍
|
